Typhoid Fever - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 55
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TF23904513CEN
Leaflet:

Download PDF Leaflet

Typhoid Fever - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Typhoid Fever - Pipeline Review, H2 2016’, provides an overview of the Typhoid Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Typhoid Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Typhoid Fever
  • The report reviews pipeline therapeutics for Typhoid Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Typhoid Fever therapeutics and enlists all their major and minor projects
  • The report assesses Typhoid Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Typhoid Fever
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Typhoid Fever
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Typhoid Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Typhoid Fever Overview
Therapeutics Development
Pipeline Products for Typhoid Fever - Overview
Pipeline Products for Typhoid Fever - Comparative Analysis
Typhoid Fever - Therapeutics under Development by Companies
Typhoid Fever - Therapeutics under Investigation by Universities/Institutes
Typhoid Fever - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Typhoid Fever - Products under Development by Companies
Typhoid Fever - Products under Investigation by Universities/Institutes
Typhoid Fever - Companies Involved in Therapeutics Development
GlaxoSmithKline Plc
Indian Immunologicals Limited
Nanotherapeutics, Inc.
Prokarium Limited
Protein Potential, LLC
Sanofi Pasteur SA
Shantha Biotechnics Limited
SK Chemicals Co., Ltd.
Zydus Cadila Healthcare Limited
Typhoid Fever - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(paratyphoid (bivalent) + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(paratyphoid + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(shigella + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Streptococcal pneumonia + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Typhella - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Typhetec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ViCRM-197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Typhoid Fever - Dormant Projects
Typhoid Fever - Discontinued Products
Typhoid Fever - Product Development Milestones
Featured News & Press Releases
Mar 11, 2013: Prokarium And University Of Birmingham Receive £0.4m Grant To Develop Next Generation Vaccines
Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine
Jun 23, 2011: Sanofi Pasteur’s Typhim Vi Receives Prequalification From World Health Organization
Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine
Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine
Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study
Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Typhoid Fever, H2 2016
Number of Products under Development for Typhoid Fever - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Typhoid Fever - Pipeline by GlaxoSmithKline Plc, H2 2016
Typhoid Fever - Pipeline by Indian Immunologicals Limited, H2 2016
Typhoid Fever - Pipeline by Nanotherapeutics, Inc., H2 2016
Typhoid Fever - Pipeline by Prokarium Limited, H2 2016
Typhoid Fever - Pipeline by Protein Potential, LLC, H2 2016
Typhoid Fever - Pipeline by Sanofi Pasteur SA, H2 2016
Typhoid Fever - Pipeline by Shantha Biotechnics Limited, H2 2016
Typhoid Fever - Pipeline by SK Chemicals Co., Ltd., H2 2016
Typhoid Fever - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Typhoid Fever - Dormant Projects, H2 2016
Typhoid Fever - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Typhoid Fever, H2 2016
Number of Products under Development for Typhoid Fever - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

GlaxoSmithKline Plc
Indian Immunologicals Limited
Nanotherapeutics, Inc.
Prokarium Limited
Protein Potential, LLC
Sanofi Pasteur SA
Shantha Biotechnics Limited
SK Chemicals Co., Ltd.
Zydus Cadila Healthcare Limited
Skip to top


Marburg Hemorrhagic Fever - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 77 pages
Marburg Hemorrhagic Fever - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 91 pages
Typhoid Fever - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Typhoid Fever - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: